Longeveron (NASDAQ:LGVN) Releases Earnings Results, Misses Expectations By $0.01 EPS

Longeveron (NASDAQ:LGVN) announced its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The business had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.33 million.

Here are the key takeaways from Longeveron’s conference call:

• ELPIS II topline results for laromestrocel in hypoplastic left heart syndrome are expected in September, with database lock planned for August 31. Management believes favorable results could support a BLA pathway, potentially including priority review.
• Longeveron ended the quarter with $10.1 million in cash and expects existing funds to support operations only through the fourth quarter of 2026. Net loss rose 22% year over year to $6.1 million, while revenue declined 10% to $0.3 million.
• Management said it has made progress on manufacturing and CMC preparations and is exploring partnerships with major pharmaceutical companies, particularly if the HLHS data are positive. A partner could provide additional capital, commercial infrastructure, and global reach.
• Laromestrocel was selected as a finalist in the XPRIZE Healthspan competition from more than 600 applicants and received a $1 million award, adding external validation to the age-related frailty program and potentially supporting future longevity partnerships.
• The company is preparing a potential 2027 Phase II trial in pediatric dilated cardiomyopathy, supported by an already-effective IND and possible eligibility for a priority review voucher, but the program remains preclinical-to-early clinical planning and requires further funding.

Longeveron Trading Up 8.4%

NASDAQ LGVN traded up $0.06 during trading on Wednesday, reaching $0.75. 843,473 shares of the stock traded hands, compared to its average volume of 2,449,461. Longeveron has a fifty-two week low of $0.47 and a fifty-two week high of $1.23. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.05. The firm has a market cap of $23.36 million, a price-to-earnings ratio of -0.66 and a beta of -0.31. The stock’s 50-day moving average price is $0.71 and its 200 day moving average price is $0.76.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings raised shares of Longeveron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wall Street Zen lowered Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. HC Wainwright decreased their price objective on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Finally, Maxim Group downgraded Longeveron from a “buy” rating to a “hold” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.50.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron at the end of the most recent quarter. Institutional investors and hedge funds own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.